| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SDCBP2 |
| Uniprot No | Q9H190 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-292aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGSMSSLYPSLEDLKVDQAIQAQVRASPKM PALPVQATAISPPPVLYPNLAELENYMGLSLSSQEVQESLLQIPEGDSTA VSGPGPGQMVAPVTGYSLGVRRAEIKPGVREIHLCKDERGKTGLRLRKVD QGLFVQLVQANTPASLVGLRFGDQLLQIDGRDCAGWSSHKAHQVVKKASG DKIVVVVRDRPFQRTVTMHKDSMGHVGFVIKKGKIVSLVKGSSAARNGLL TNHYVCEVDGQNVIGLKDKKIMEILATAGNVVTLTIIPSVIYEHMVKKLP PVLLHHTMDHSIPDA |
| 预测分子量 | 34 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是一些关于SDCBP2重组蛋白的模拟参考文献示例(实际文献需通过学术数据库检索)：
1. **文献名称**: "Recombinant SDCBP2 Protein Promotes Tumor Cell Invasion via EGFR Signaling in Colorectal Cancer"
**作者**: Lee H, et al.
**摘要**: 研究报道了SDCBP2重组蛋白通过调控EGFR信号通路增强结直肠癌细胞的侵袭能力，揭示了其在肿瘤转移中的潜在作用机制。
2. **文献名称**: "Expression and Purification of Functional SDCBP2 in a Bacterial System"
**作者**: Zhang Y, et al.
**摘要**: 描述了利用大肠杆菌表达系统高效表达和纯化具有生物活性的SDCBP2重组蛋白的方法，并验证其与细胞表面受体的结合能力。
3. **文献名称**: "SDCBP2 as a Novel Biomarker: Role of Recombinant Protein in Angiogenesis Regulation"
**作者**: Gupta S, et al.
**摘要**: 通过体外实验证明，SDCBP2重组蛋白可通过调控VEGF通路抑制血管生成，提示其作为抗肿瘤治疗的潜在靶点。
4. **文献名称**: "Structural Characterization of SDCBP2 and Its Interaction with Syndecan-1"
**作者**: Müller P, et al.
**摘要**: 利用X射线晶体学解析了SDCBP2重组蛋白的结构，并阐明其与Syndecan-1蛋白的相互作用界面，为功能研究提供结构基础。
---
**注意**：以上文献为模拟内容，实际研究请通过**PubMed/Google Scholar**以关键词“SDCBP2 recombinant protein”或“SDCBP2 syntenin-2”检索最新文献。
SDCBP2 (Syndecan Binding Protein 2), also known as STC2 or MDA-9. is a member of the PDZ domain-containing protein family involved in diverse cellular processes, including cell adhesion, signal transduction, and extracellular matrix interactions. Initially identified as a syndecan-interacting protein, it plays a role in regulating syndecan-mediated signaling pathways, particularly those linked to tumor progression and metastasis. Structurally, SDCBP2 contains two tandem PDZ domains that mediate protein-protein interactions, enabling its participation in dynamic molecular networks. It is implicated in modulating integrin signaling, cytoskeletal organization, and growth factor receptor trafficking, influencing cell migration, invasion, and survival.
In cancer biology, SDCBP2 is often overexpressed in malignancies such as melanoma, breast, and pancreatic cancers, where it promotes angiogenesis, epithelial-mesenchymal transition (EMT), and chemoresistance. Its interaction with syndecans and integrins enhances cross-talk between tumor cells and the microenvironment, facilitating metastatic dissemination. Beyond oncology, SDCBP2 has roles in neurological disorders and inflammatory responses, though these are less characterized.
Recombinant SDCBP2 protein is produced using expression systems like *E. coli* or mammalian cells (e.g., HEK293), followed by affinity purification (e.g., His-tag). It is widely utilized for *in vitro* studies to dissect molecular mechanisms, screen therapeutic agents, or develop diagnostic tools. Functional validation typically involves binding assays (e.g., co-immunoprecipitation) and activity tests (e.g., cell migration assays). Despite its therapeutic potential, challenges remain in understanding isoform-specific functions and optimizing targeted delivery. Current research focuses on leveraging recombinant SDCBP2 to design inhibitors disrupting its PDZ domain interactions, offering promise for anti-metastatic therapies.
×
